Is Lexicon Pharmaceuticals, Inc. (LXRX) a Buy, Sell, or Hold?
Lexicon Pharmaceuticals, Inc.
NASDAQ:LXRX
$2.12 USD
-$0.05 (-2.3%)
- Volume
- 1.54M
- Average Volume
- 3.22M
- Market Capitalization
- $941.7M
- P/E Ratio
- -29.69
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $2.68
- Year Low
- $1.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $18.79
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Michael S. Exton |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | LXRX |
| CUSIP | 528872302 |
| CIK | 0001062822 |
| Web | https://www.lexpharma.com |
| Phone | 281 863 3000 |
| Currency | USD |
| Employees | 81 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.28 |
| Payout Ratio | 0.00 |
| Current Ratio | 18.79 |
| Quick Ratio | 18.77 |
| Cash Ratio | 3.85 |
Sales & Book Value
| Annual Sales | $49.8M |
| Price / Sales | 13.52 |
| Cash Flow | -0.10 |
| Price / Cash Flow | -24.27 |
| Price / Book | 4.18 |
Price Target and Rating
| Average Stock Price Forecast | $6.00 |
| High Stock Price Forecast | $6.00 |
| Low Stock Price Forecast | $6.00 |
| Forecast Upside/Downside | -64.67% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 14 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.14 |
| Trailing P/E Ratio | -29.69 |
| PEG Ratio | -0.11 |
| P/E Growth | -0.11 |
| Net Income | $-50.34M |
| Net Margin | -37.46% |
| Pretax Margin | -37.46% |
| Return on Equity | -18.64% |
| Return on Assets | -9.71% |
Financials Score
| AltmanZ Score | -0.92 |
| Piotroski Score | 4.00 |
| Working Capital | 176.13M |
| Total Assets | 268.82M |
| Ebit | -18M |
| Market Cap | 963.91M |
| Total Liabilities | 65.96M |
Poll Results
About Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Stock
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas. ...
Here's Why You Should Add LXRX Stock to Your Portfolio Now
2026-06-22 11:41:17
Lexicon advances sotagliflozin into new indications while its obesity and pain programs progress, setting the stage for multiple pipeline milestones.
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
2026-06-11 09:45:55
One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
2026-06-03 08:00:00
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
2026-05-28 08:30:00
THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 2:00 p.m. ET in New York City.
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
2026-05-12 08:30:00
THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on May 19, 2026.
Lexicon Pharmaceuticals Q1 Earnings Call Highlights
2026-05-08 16:12:11
Lexicon Pharmaceuticals NASDAQ: LXRX executives highlighted progress across late-stage regulatory programs and efforts to bolster the company's financial position during the company's first-quarter 2026 earnings call on May 7.
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
2026-05-07 17:11:13
Lexicon Pharmaceuticals, Inc. (LXRX) Q1 2026 Earnings Call Transcript
Lexicon Pharmaceuticals (LXRX) Reports Break-Even Earnings for Q1
2026-05-07 09:55:55
Lexicon Pharmaceuticals (LXRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.07 per share a year ago.
Frequently Asked Questions
-
What is the current Lexicon Pharmaceuticals, Inc. (LXRX) stock price?
-
Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX) stock price is $2.12 in the last trading session. During the trading session, LXRX stock reached the peak price of $2.68 while $1 was the lowest point it dropped to. The percentage change in LXRX stock occurred in the recent session was --2.3% while the dollar amount for the price change in LXRX stock was -$-0.05.
-
LXRX's industry and sector of operation?
-
The NASDAQ listed LXRX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of LXRX?
-
Brian T. Crum | Senior Vice President, General Counsel & Secretary
Craig Granowitz | Senior Vice President & Chief Medical Officer
Michael Exton | Chief Executive Officer & Director
Suma Gopinathan | Senior Vice President of Discovery
Scott Coiante | Senior Vice President & Chief Financial Officer -
How many employees does LXRX have?
-
Number of LXRX employees currently stands at 81. LXRX operates from 2445 Technology Forest Boulevard, The Woodlands, TX 77381, US.
-
Link for LXRX official website?
-
Official Website of LXRX is: https://www.lexpharma.com
-
How do I contact LXRX?
-
LXRX could be contacted at phone #281 863 3000 and can also be accessed through its website. LXRX operates from 2445 Technology Forest Boulevard, The Woodlands, TX 77381, US.
-
How many shares of LXRX are traded daily?
-
The average number of LXRX shares traded daily for last 3 months was 3.22M.
-
What is the market cap of LXRX currently?
-
The market value of LXRX currently stands at $941.7M with its latest stock price at $2.12